J Carulla
11 Papers
43 Citations
J Carulla is an academic researcher. The author has contributed to research in topics: Regimen & Chemotherapy. The author has an hindex of 7, co-authored 11 publications.
Chat about Author
Papers
Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.
Joaquim Bellmunt,Joan Albanell,O. S. Gallego,Antoni Ribas,Vicente P,J Carulla,J. A. De Torres,Joan Morote,MV Lopez,Solé La +9 more
TL;DR: A Phase II trial with a new regimen of methotrexate, carboplatin, and vinblastine (M‐CAVI) was conducted for patients with bladder cancer who could not receive cisplatin‐based chemotherapy.
50
Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero,Fredy Rojo,Irene Marimón,Maurizio Voi,Joan Albanell,Marta Guix,Federico Vazquez,J Carulla,Michael K. Cooper,Jordi Andreu,Anne Van Vreckem,Joaquim Bellmunt,Veeraswamy Manne,James A. Manning,Carmen Garrido,Enriqueta Felip,Josep M. del Campo,Mónica García,Sonia Valverde,José Baselga +19 more
TL;DR: BMS-214662 can be safely delivered in both the 1-hour and 24-hours infusions at biologically active doses, with the preclinical, PK, and pharmacodynamic profiles favoring the 24-hour schedule.
33
Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity
Joaquim Bellmunt,M. Navarro,Serafin Morales,L. Jolis,J Carulla,H. Knobell,M. Vilardell,Solé La +7 more
TL;DR: It is concluded that capillary microscopy may demonstrate the vascular damage induced by BLEO even in asymptomatic patients.
18
Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer.
TL;DR: The addition of folinic acid could improve the efficacy of tegafur by means of biochemical modulation.
15
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.
Joaquim Bellmunt,Antoni Ribas,Joan Albanell,Begoña Bermejo,R. Vera,J. A. De Torres,Joan Morote,M. A. Lopez-Pacios,J. M. Banus,Angels Rovirosa,J Carulla,Solé La +11 more
TL;DR: M-CAVI is an active and well-tolerated regimen that should be compared in terms of response rate and survival with a cisplatin-based regimen for invasive bladder cancer.
14